🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans

Sudan Loganathan

Stock Analyst at Stephens

(4.10)
# 1,679
Out of 5,144 analysts
36
Total ratings
60.6%
Success rate
18.9%
Average return

Stocks Rated by Sudan Loganathan

ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.35
Upside: +270.37%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $144.35
Upside: +52.41%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $17.18
Upside: +74.62%
Kymera Therapeutics
Mar 2, 2026
Reiterated: Buy
Price Target: $110 → $100
Current: $121.52
Upside: -17.71%
Arvinas
Feb 25, 2026
Reiterated: Buy
Price Target: $15 → $18
Current: $6.82
Upside: +163.93%
Pyxis Oncology
Nov 24, 2025
Reiterated: Buy
Price Target: $13 → $8
Current: $1.44
Upside: +455.56%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $5.40
Upside: n/a
C4 Therapeutics
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $2.53
Upside: n/a
Faeth Therapeutics
Jun 30, 2025
Reiterated: Buy
Price Target: $5 → $35
Current: $9.04
Upside: n/a
Exelixis
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $68.50
Upside: n/a
Reiterated: Buy
Price Target: $20 → $30
Current: $14.24
Upside: n/a
Downgraded: Hold
Price Target: $8 → $1
Current: -
Upside: n/a
Reiterated: Buy
Price Target: $25 → $5
Current: $1.35
Upside: n/a
Initiated Coverage: Buy
Price Target: $15
Current: $13.58
Upside: n/a
Initiated Coverage: Buy
Price Target: $51
Current: $27.40
Upside: n/a
Initiated Coverage: Hold
Price Target: $25
Current: $3.20
Upside: n/a
Rated: Buy
Price Target: $25
Current: $19.37
Upside: n/a